Category: Press Releases

Google Cloud Network’s Global Network Edge Locations Will Expand Fortinet’s POP Coverage for Universal SASE Customers

SUNNYVALE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) —

News Summary
Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced the expansion of its SASE Points-of-Presence (POPs) to new locations through a partnership with Google Cloud. The partnership allows Fortinet to leverage Google Cloud’s global network edge locations closest to their regions of presence, which deliver dedicated interconnect and 99.99% service availability, to accelerate the expansion of Fortinet’s Universal SASE solution.

Single-vendor SASE is a critical architecture organizations adopt to connect their hybrid workforces securely. A robust network of SASE POPs that are scalable and globally available is crucial to delivering a superior user experience while enabling a strong security posture.

“By leveraging Google Cloud, Fortinet Universal SASE is even better positioned to serve a more extensive global footprint, ensuring that customers can seamlessly connect and secure their hybrid workforces to critical applications,” said Michael Xie, Founder, President, and Chief Technology Officer of Fortinet. “This partnership will expand our global POP resources and accelerate customer adoption of Fortinet’s Universal SASE solution. And because our SD-WAN solution is natively integrated with our SASE offering, Fortinet’s global SD-WAN customers now have an even broader ability to easily adopt integrated cloud-delivered security to implement a comprehensive Universal SASE solution.”

“Organizations worldwide rely on the Google Cloud for critical networking and access,” said Muninder Sambi, Vice President and GM of Networking at Google Cloud. “Our expanded partnership with Fortinet can enable high uptime for customers looking to support their hybrid workforces with Fortinet’s SASE solution, along with the advantages of using Google Cloud’s Cross-Cloud Network, which include lower costs and improved application experiences.”

Converging Networking and Security with Fortinet Universal SASE
Fortinet’s Universal SASE solution uniquely converges networking and security to support today’s hybrid workforce, expanding network edges and new microbranches to enable secure access to applications while providing high ROI through consolidation and improved digital user experience. Fortinet’s solution includes an extended portfolio of critical technologies and services that enable organizations to adopt a zero-trust security posture by effectively applying and monitoring context-based policies regardless of the resource a user is accessing. Fortinet Universal SASE offers a high-performance and scalable cloud network with best-in-class AI-powered security, unified management, and end-to-end digital experience monitoring to ensure secure access to web, corporate, and SaaS applications.

Fortinet is the pioneer and leader of secure SD-WAN, the foundation of its Universal SASE solution. Universal SASE uses the same FortiOS operating system and AI-powered security services as its secure SD-WAN and cloud-delivered security service edge (SSE) solutions. This unique integrated approach extends secure web gateway (SWG), zero-trust network access (ZTNA), cloud access security broker (CASB), and Firewall-as-a-Service (FWaaS) solutions to its Universal SASE solution, enabling seamless connectivity, consistent end-to-end threat protection, and optimal user experience.

Additional Resources

• Learn more about Fortinet Universal SASE.
• Learn more about Fortinet’s recent SASE recognition.
• Learn about Fortinet’s free cybersecurity training, which includes broad cyber awareness and product training. As part of the Fortinet Training Advancement Agenda (TAA), the Fortinet Training Institute also provides training and certification through the Network Security Expert (NSE) Certification, Academic Partner, and Education Outreach programs.
• Learn more about FortiGuard Labs threat intelligence and research and Outbreak Alerts, which provide timely steps to mitigate breaking cybersecurity attacks.
• Learn more about Fortinet’s FortiGuard Security Services portfolio.
• Read about how Fortinet customers are securing their organizations.
• Follow Fortinet on Twitter, LinkedIn, Facebook, and Instagram. Subscribe to Fortinet on our blog or YouTube.

About Fortinet
Fortinet (NASDAQ: FTNT) is a driving force in the evolution of cybersecurity and the convergence of networking and security. Our mission is to secure people, devices, and data everywhere, and today we deliver cybersecurity everywhere you need it with the largest integrated portfolio of over 50 enterprise-grade products. Well over half a million customers trust Fortinet’s solutions, which are among the most deployed, most patented, and most validated in the industry. The Fortinet Training Institute, one of the largest and broadest training programs in the industry, is dedicated to making cybersecurity training and new career opportunities available to everyone. FortiGuard Labs, Fortinet’s elite threat intelligence and research organization, develops and utilizes leading-edge machine learning and AI technologies to provide customers with timely and consistently top-rated protection and actionable threat intelligence. Learn more at https://www.fortinet.com, the Fortinet Blog, and FortiGuard Labs.

FTNT-O

Copyright © 2023 Fortinet, Inc. All rights reserved. The symbols ® and denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiMail, FortiSandbox, FortiADC, FortiAI, FortiAIOps, FortiAntenna, FortiAP, FortiAPCam, FortiAuthenticator, FortiCache, FortiCall, FortiCam, FortiCamera, FortiCarrier, FortiCASB, FortiCentral, FortiConnect, FortiController, FortiConverter, FortiCWP, FortiDB, FortiDDoS, FortiDeceptor, FortiDeploy, FortiDevSec, FortiEdge, FortiEDR, FortiExplorer, FortiExtender, FortiFirewall, FortiFone, FortiGSLB, FortiHypervisor, FortiInsight, FortiIsolator, FortiLAN, FortiLink, FortiMoM, FortiMonitor, FortiNAC, FortiNDR, FortiPenTest, FortiPhish, FortiPlanner, FortiPolicy, FortiPortal, FortiPresence, FortiProxy, FortiRecon, FortiRecorder, FortiSASE, FortiSDNConnector, FortiSIEM, FortiSMS, FortiSOAR, FortiSwitch, FortiTester, FortiToken, FortiTrust, FortiVoice, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLM and FortiXDR. Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments.

Media Contact:	Investor Contact:	Analyst Contact:
Michelle Zimmermann Fortinet, Inc. 408-235-7700 pr@fortinet.com	Peter Salkowski Fortinet, Inc. 408-331-4595 psalkowski@fortinet.com	Brian Greenberg Fortinet, Inc. 408-235-7700 analystrelations@fortinet.com

GlobeNewswire Distribution ID 8949252

MUMBAI, India, Oct. 16, 2023 (GLOBE NEWSWIRE) — World Lacrosse’s decades-long vision to return the sport to the Olympic stage has been realized, with the International Olympic Committee approving lacrosse’s inclusion in the 2028 Olympic Games in Los Angeles.

The approving vote today by the IOC Session – which includes 99 international sport leaders – was the last step of a formal process initiated by the LA28 Organizing Committee last year to add new sports to the Games in Los Angeles.

LA28 will mark the third Olympic appearance for North America’s first sport that is now played in nearly 100 countries around the world, after it was contested in 1904 (St. Louis) and 1908 (London). Lacrosse was later featured as a demonstration sport in three Olympics: Amsterdam 1928, Los Angeles 1932 and London 1948.

To celebrate the inclusion of lacrosse in the Olympics and recognize the magnitude of the moment, World Lacrosse will launch A New Era, a campaign aimed at propelling the sport into its next generation via pivotal growth in participation, popularity and sustainability.

In 2028, men’s and women’s lacrosse will be competed in sixes, an incredibly fast-paced, compact version of the sport at the intersection of field and box lacrosse. It offers an inclusionary opportunity to all lacrosse athletes and an easier entry point for new players, and is characterized by an accelerated, open style of play with quick transitions and non-stop, high-scoring action.

Developed in 2018, sixes has advanced global growth, increased accessibility and approachability, created greater competitive balance, and reduced cost and complexity of participation and event staging. It is the next generation version of the game.

World Lacrosse President Sue Redfern said: “There is no greater designation than to be recognized as an Olympic sport. The global lacrosse family has been passionately working toward reaching this pinnacle for more than a decade. This seminal achievement would not have been possible without the effort of many visionary and dedicated individuals who collectively recognized that Olympic inclusion is the most significant catalyst for the continued growth of a sport. I offer our sincere gratitude to LA28 and the IOC for allowing us to realize our vision; now is our time to shine and show the world how lacrosse contributes to a better tomorrow.”

World Lacrosse CEO Jim Scherr said: “Today is a remarkable moment in the history of both lacrosse and the Olympic Games. The inclusion of lacrosse in the 2028 Olympics in Los Angeles is a testament to our sport’s enduring legacy, worldwide popularity and unique ability to bring people together. It also signifies the culmination of an extraordinary journey to return North America’s first game to the Olympics, a journey made possible by the unwavering passion of our lacrosse community.”

“This decision reaffirms the Olympic values of unity, diversity and athletic excellence. We eagerly anticipate sharing the beauty of lacrosse with the world and take immense pride in participating in an Olympic Games that champions inclusion and diversity. Together, we will make history on the grandest stage in sports and inspire future generations with the power of lacrosse.”

Lacrosse was originated by North America’s Indigenous peoples in the 12^th century and remains a significant part of Native American culture, highlighted by the Haudenosaunee Confederacy’s participation in World Lacrosse events.

Uniquely, men’s and women’s organized lacrosse developed in parallel dating back to the 19^th century, led by the United States, Canada, the United Kingdom and Australia. International Federations were separately established in the 1970s, then merged in 2008 with a united vision of returning to the Olympics.

Following recognition by numerous global sports bodies and provisional status from the IOC in 2018, World Lacrosse’s Olympic vision became possible following full recognition by the IOC in 2021. The following year, the sport was shortlisted for inclusion in LA28 and went through a comprehensive evaluation and proposal process, leading to today’s final decision.

Over the last two decades, lacrosse has seen unprecedented growth, doubling its membership from 45 to 90 National Federations. Lacrosse is now played in all five continental regions, with four continents represented in the world top-10 rankings for both men and women.

Lacrosse is one of five new sports being added to the sport program for LA28, joining baseball/softball, cricket, flag football and squash.

As the global lacrosse community and the Olympic family unite in celebration, the 2028 Olympic Games in Los Angeles promise to be a stage for lacrosse’s very best athletes as they vie for the sport’s highest honor.

What They’re Saying

Joe Tsai, Alibaba Group Chairman/Lacrosse supporter in North America and internationally: “This momentous occasion is a testament to the unwavering dedication and persistence of the global lacrosse community. Together, we’ve shown LA28 and the IOC that lacrosse is an electrifying sport with a rich heritage, diverse participation and immense global appeal. The inclusion of lacrosse in the Olympic Games marks a pivotal moment for the sport’s growth, and we’re excited to showcase thrilling competition while uniting fans from all corners of the world on the grandest sporting stage.”

Marc Riccio, USA Lacrosse CEO: “We are thrilled that the International Olympic Committee has voted to include lacrosse in the 2028 Summer Olympics in Los Angeles. In some ways, it feels like we’ve reached the finish line with so many people working towards this goal for so many years. In reality, this is the beginning of a bright new future. The Olympics gives our sport the platform and visibility to achieve unprecedented growth. We can’t wait to get started on the next chapter in the sport’s history.”

Jane Lee, Korea Women’s National Team/World Lacrosse Athletes’ Commission Chair & Board Member: “I am thrilled that our collective efforts have cumulated in this monumental achievement. It is an astounding success, and I couldn’t be more excited about the milestone we have reached together. As athletes, this is the pinnacle of our sport, and we would like to thank World Lacrosse and the entire lacrosse community around the world for their dedication, passion and unwavering commitment in this journey for Olympic inclusion. It is a true celebration of the rich history of lacrosse, and a testament to the unity of our sport.”

Paul Rabil, Premier Lacrosse League Co-Founder/2x World Champion (USA): “As an athlete, this is the dream. And today, the next generation lacrosse player picking up a stick for the first time can dream big. There have never been more opportunities for players at the youth, high school, college and professional levels. Our path of ascendency in just five years at the PLL proves the incredible potential and possibilities of the sport – where today’s news further cements lacrosse as the next great global game. A special thank you to LA28 and the IOC for believing in our vision. To World Lacrosse and every lacrosse organization around the world that continues to invest in the growth of the game: thank you. We’re back.”

Brett Frood, National Lacrosse League Commissioner: “The legacy popularity and growth of lacrosse in North America is poised for mass acceleration, inclusive of traditional epicenters and aspiring hotbeds alike. There is a robust appetite for all disciplines of the game and this Olympic opportunity will fortify a collective rise the tide mentality. Sixes is box lacrosse’s close cousin, so the National Lacrosse League looks forward to doing its part in welcoming, surprising and energizing new and existing fans to our uniquely entertaining sport and game experience. On behalf of the NLL, we congratulate the LA28 Organizing Committee and World Lacrosse and fervently join the global lacrosse community in celebrating this monumental moment.”

Abi Jackson, Athletes Unlimited Director of Lacrosse: “The Olympic Games are the pinnacle of athletic competition, and a dream for every athlete. Having lacrosse be part of the Los Angeles 2028 Olympic Games is a monumental moment for our sport and the millions of athletes who play across the United States. We are also thrilled that our decorated professionals who have dominated in global competition for years will finally be able to showcase their talents on sport’s biggest stage.”

Lena Stede, Germany Women’s National Team/German Lacrosse Association Athletes’ Commission Member: “For us athletes, the IOC’s decision to integrate the sport of lacrosse into the 2028 Olympic Games shows an incredible appreciation for the performance that has been shown on and off the field for decades, with hard work from everyone involved and without large financial resources. The fact that we can now represent our sport at the largest sporting event in the world makes us incredibly proud. The decision shows how much potential the sport of lacrosse has to offer, and we athletes will work even harder to fully develop this potential.”

Christy Cahill
World Lacrosse
+16177774489
ccahill@worldlacrosse.sport

GlobeNewswire Distribution ID 8949784

Intratumoral Nidlegy followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone

PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients

Nidlegy is the first immunocytokine product to show positive data in a Phase III randomized clinical trial

The results will be presented at an upcoming international medical meeting and submitted to peer-reviewed journal, as well as to regulatory authorities

Nidlegy is also currently developed for the treatment of high-risk locally advanced basal cell carcinoma and other types of non-melanoma skin cancers

SIENA, Italy and MUMBAI, India, Oct. 16, 2023 (GLOBE NEWSWIRE) — Philogen S.p.A. (BIT:PHIL) and Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) are pleased to announce positive results from the Phase III PIVOTAL trial in patients with locally advanced fully resectable melanoma (NCT02938299). The study compared neoadjuvant intratumoral Nidlegy (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm). Patients were allowed to receive approved adjuvant systemic therapies after surgery in both arms.

According to the protocol, the primary endpoint of the study was the Recurrence-Free Survival (RFS) assessed per Blinded Independent Central Review (BICR) for patients treated with Nidlegy, compared to the control arm. At median follow-up of 27.6 months in both groups, the study met its primary endpoint with a statistically significant and clinically meaningful improvement in RFS of the treatment arm compared to the control arm. This positive outcome was consistently in line with the Investigators’ Assessment: a significant reduction of the hazard risk ratio of 33% (HR = 0.67) and 37% (HR = 0.63), respectively, favoring the treatment arm, was observed both in the BICR and in the Investigators’ Assessment analysis.

Treatment-related adverse events observed with Nidlegy were benign and manageable, consistent with the proposed mechanism of action and with the favorable safety profile previously reported in the Phase II study [Danielli et al. (2015) Cancer Immunol. Immunother., 64, 999]. Grade 3 adverse events occurred in 24.8% of the treated patients. Neither grade 4 toxicity nor treatment-related deaths were observed in the study. Nidlegy treatment was not associated with the induction of autoimmune conditions.

PIVOTAL enrolled 257 patients in Europe across 22 clinical centers in Germany, Italy, France and Poland. The results, including sub-group analyses, will be presented at a forthcoming medical meeting.

Nidlegy is also being developed in dedicated Phase II clinical trials for the treatment of aggressive forms of non-melanoma skin cancer, including high-risk locally advanced basal cell carcinoma and cutaneous squamous cell carcinoma.

Prof. Dario Neri, co-founder, CEO and CSO of Philogen, commented: “We are extremely pleased to announce positive topline data emerging from our PIVOTAL program in locally advanced resectable melanoma. The clinical data in melanoma and high-risk non melanoma skin cancers bode well for the possible adoption of intralesional Nidlegy in a series of Dermato-Oncology indications. Philogen is currently executing six additional advanced clinical trials with registration potential featuring either Nidlegy or Fibromun, the company’s most advanced product candidates, as active ingredients.”

Alfredo Covelli, MD, Chief Medical Officer of Philogen, commented: “Neoadjuvant cytokine therapy for the treatment of locally advanced skin cancers enables a robust expansion of tumor-infiltrating lymphocytes. By anchoring interleukin-2 and tumor necrosis factor within the tumor mass through the L19 antibody moiety, we minimize systemic side effects while mounting a systemic robust anti-cancer immune response. This Phase 3 study merged the intralesional approach with IL2, pioneered by Prof. Claus Garbe more than 20 years ago, with the concepts of antibody-based tumor targeting, and with neoadjuvant therapy in locally advanced melanoma. The approach may find a broad applicability in different types of cancer.”

Hellen De Kloet, Business Head – Western Europe and ANZ, Sun Pharma, said: “We are looking forward to commercializing Nidlegy in Europe, Australia and New Zealand as the first neoadjuvant immunotherapy for patients with resectable advanced melanoma. Nidlegy, as an intralesional therapeutic option, addresses the existing significant unmet need for effective and well-tolerated treatments in patients, before undergoing surgery.”

Philogen and Sun Pharma announced on May 30^th, 2023, to have entered into distribution, license and supply agreement for commercializing Nidlegy in Europe, Australia and New Zealand for the treatment of skin cancers.

About Nidlegy (Daromun)

Nidlegy is a biopharmaceutical product, proprietary to Philogen, designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF which are manufactured independently, and which are mixed prior to intralesional administration. The L19 antibody is specific to the Extra Domain B of Fibronectin, a protein expressed in tumors (and other diseases) but absent in most healthy tissues. Interleukin 2 (IL2) and Tumor Necrosis Factor (TNF) are pro-inflammatory cytokines with anti-tumor activity. Nidlegy is currently being investigated in two Phase III clinical trials for the treatment of locally advanced melanoma, and in Phase II clinical trials for the treatment of High-Risk Basal Cell Carcinoma and other non-melanoma skin cancers.

About PIVOTAL Phase III study

PIVOTAL is a phase III, international, multi-center, randomized, comparator-controlled, parallel-group study evaluating the efficacy and safety of intratumoral injections of Nidlegy as a neoadjuvant treatment, followed by standard-of-care treatment (surgery), as opposed to standard-of-care treatment (i.e., surgery alone), in melanoma patients with locally advanced, fully resectable cutaneous, sub-cutaneous (including satellite/in transit metastases), or nodal metastases, accessible to intratumoral injection. For both arms, adjuvant treatment with approved drugs was allowed. Nidlegy was injected intralesionally up to four times, once a week before surgery.

About locally advanced fully resectable melanoma

Melanoma is skin tumor which begins when melanocytes start growing without control. Melanocytes are found in the basal layer of the epidermis at the boundary with the next layer (the dermis). Locally advanced melanoma is a metastatic cancer in which neoplastic lesions have spread to drainage area of regional lymph nodes and can appear as micrometastases, satellite/in transit metastases, and/or lymph node metastases. To date, these patients with resectable disease receive surgery, possibly followed by approved adjuvant systemic therapies. There is no approved drug for the treatment of locally advanced fully resectable melanoma in the neoadjuvant setting.

About Philogen

Philogen (https://www.philogen.com) is an Italian-Swiss biotechnology company specialized in the research and development of innovative pharmaceuticals for the treatment of cancer. The Group’s main therapeutic strategy is based on the use of ligands capable to selectively deliver potent payloads (such as pro-inflammatory cytokines, drugs or radionuclides) to the tumor mass, sparing healthy tissues. Over the years, Philogen has discovered and developed monoclonal antibody- and small molecule-based ligands with high affinity to tumor-associated antigens. The Group is headquartered in Siena, Italy, with a subsidiary and research center in Zurich, Switzerland. In addition to its main oncology focus, Philogen is also active in the development of novel pharmaceuticals for the treatment of chronic and debilitating conditions.

About Sun Pharmaceutical Industries Ltd. (CIN – L24230GJ1993PLC019050):

Sun Pharma is the world’s fourth largest specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on “X” @SunPharma_Live

FOR MORE INFORMATION:

Philogen – Investor Relations

IR@philogen.com – Emanuele Puca | Investor Relations

Sun Pharma

Investors			Media
Dr. Abhishek Sharma			Gaurav Chugh
Tel	+ 91 22 4324 4324, Ext 2929		Tel	+ 91 22 4324 4324, Ext 5373
Tel Direct	+ 91 22 43242929		Tel Direct	+ 91 22 43245373
Mobile	+ 91 98196 86016		Mobile	+ 91 98104 71414
E mail	abhi.sharma@sunpharma.com		E mail	gaurav.chugh@sunpharma.com

Forward-Looking Statements

The forward-looking statements contained in this press release may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding anticipated advancement of preclinical development efforts and initiation and progression of clinical trials; anticipated enrollment in and progression of Philogen’s clinical trials; the availability of data from clinical trials and preclinical studies; anticipated regulatory filings; the therapeutic potential of Philogen’s product candidates; Philogen’s ability to achieve planned milestones. Philogen may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Philogen’s and its partners’ abilities to meet other anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Philogen’s product candidates by Philogen or its partners; the risk that Philogen may not realize the intended benefits of its technology; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Philogen’s product candidates; risks related to Philogen’s ability to maintain existing collaborations and realize the benefits thereof; expectations for regulatory approvals to conduct trials or to market products; other factors which could cause our actual result to differ from those contained in the forward-looking statements, as also described in greater detail in the Risk Factors section in the prospectus drafted by Philogen and approved by Consob on February 17, 2021. Any forward-looking statements contained in this press release speak only as of the date hereof, and Philogen expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. The information and contents of this press release do not: (i) constitute an order or an offer to purchase or to sell financial products or financial services; (ii) relate to special investment goals or to the financial situation or particular requirements of specific users. All information presented, reports published, and opinions expressed are intended purely for information purposes, and do not constitute an offer for the conclusion of a contract or other legal transaction. In particular, the content of the press release is not to be understood as an invitation or recommendation to buy or sell securities of Philogen, or as an advertisement for securities of Philogen. Neither does it constitute an offer to participate in any other transaction, including (but not restricted to) trading in derivatives. The mere use of the website does not give rise to any contractual relationship of any kind between the user and Philogen. Philogen expressly draws your attention to the fact that its share price is subject to fluctuation, and that the future development of the share price cannot be derived either from the previous price history or from the information and content shown on this website. Results achieved in the past provide no guarantee in regard to the future development of the share price. Philogen provides no guarantee of any kind that the capital invested will increase in value or maintain its value. In light of these given risks, we strongly advise you to seek professional advice before making any investment decision. The material contained on the website does not relieve the user from having to make his own decisions. This press release may contain links to external websites of third parties (external links) the content of which is outside the sphere of influence of Philogen. Visiting and using such websites that are accessible via such links are subject to the conditions of the data protection policy of these websites and the liability of the respective operators. Philogen accepts no responsibility and offers no guarantee of any kind for the content or websites of third parties and gives no assurances of any kind in this regard. Philogen accepts no responsibility for the data protection policy and customer information of websites of third parties and shall not be liable for the content or web pages of third parties which are linked to the Philogen website, or which display the Philogen website in frames.

GlobeNewswire Distribution ID 1000864365

COPENHAGEN, Denmark, Oct. 16, 2023 (GLOBE NEWSWIRE) — Copenhagen Infrastructure Partners has reached final close for its two new funds, CI Advanced Bioenergy Fund I (CI ABF I) and CI Green Credit Fund I (CI GCF I) with total LP commitments of EUR ~2bn. 2023 has been a record year for CIP, as in addition to this final close announcement, CIP also held first close for its flagship fund, CI V, at EUR 5.6bn.

With commitments from investors across the Nordics, Europe, and Asia Pacific, CI GCF I closed at EUR ~1bn with an additional EUR ~200m in co-investments to date. ABF I closed at EUR 750m. The funds’ investor bases are comprised of institutional investors, primarily pension funds, life insurance companies, sovereign wealth funds, family offices, asset managers, and corporate investors.

The two funds make up integral parts of CIP’s distinct greenfield renewable energy infrastructure focused fund strategies. The Advanced Bioenergy Fund I is expected to contribute substantially to producing clean fuels such as renewable natural gas from food waste, agricultural residues and other organic waste streams, displacing carbon-emitting fuels and mitigating negative environmental impacts from these waste streams. The Green Credit Fund provides debt financing with subordinated risk characteristics for renewable energy projects globally, contributing to decarbonizing the power market.

CI GCF I focuses on providing private project finance debt with subordinated risk characteristics supporting renewable energy projects in Europe, North America, and selective jurisdictions in the Asia Pacific region. The project focus is on green- and brownfield projects in renewable energy infrastructure. The fund’s main focus will be on direct investments, but it also has the ability to participate in risk-sharing transactions.

“Reaching this milestone together with a strong group of global LPs allows us to continue identifying new investment opportunities, and work with strong developers on executing the renewable energy build-out. We believe private credit in the renewable energy space is a natural addition to the strong CIP fund portfolio, and it offers our LPs a new and attractive way to deploy capital into the energy transition while leveraging CIP’s strong skills and heritage,” says Jakob Groot, partner and co-head of CIP’s credit platform with partner Nicholas Blach-Petersen.

As of October 13, 2023, CI GCF I has already closed three investments and committed a total of EUR 236m. The fund has a portfolio of renewable energy infrastructure opportunities across a range of European countries as well as North America, and it continues to see a strong demand for this type of debt capital.

The Advanced Bioenergy Fund I focuses on investments in advanced bioenergy infrastructure, in particular in Europe. It enables institutional investors to contribute to the energy transition and participate in the decarbonization of hard-to-abate sectors through the production of advanced biofuels and biogas – while delivering cost-efficient and circular solutions for environmental and organic waste challenges. Investments will be dark green (as defined in the EU regulation Article 9) based on sustainable feedstock such as waste wood, agricultural biowaste, household biowaste and industrial biowaste. The offtake products include green gas and green fuels, such as renewable natural gas (RNG), liquified natural gas (bio-LNG), and second generation bioethanol.

“We are pleased to welcome the new investors in CI ABF I and are delighted that investors generally share our confidence in the market for advanced bioenergy projects. There is a very strong market demand for green gas and green fuels and circular solutions which is provided by CI ABF I’s investment strategy and underpinned by robust regulatory drivers both in the EU and the US. We have a strong pipeline of projects in these markets that we look forward to progressing even further,” says Thomas Dalsgaard, partner in the Advanced Bioenergy Fund.

On one project, CI ABF I has already taken final investment decision to begin construction, and exclusivity has been secured on several industrial-scale advanced bioenergy projects. The projects are located in Denmark, The Netherlands, Belgium, and Spain and are expected to produce Renewable Natural Gas (RNG) and biogenic CO2 from food waste, industrial waste and agricultural waste.

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focuses on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages ten funds and has to date raised approximately EUR 26bn for investments in energy and associated infrastructure from more than 150 international institutional investors. CIP has approximately 400 employees and 12 offices around the world. For more information, visit www.cip.com

For further information, please contact:

Thomas Kønig, Partner – Investor Relations | +45 7070 5151 | TKON@cip.com
Stephanie R. Brokhattingen, Partner – Investor Relations | +45 7070 5151 | SBR@cip.com
Oliver Routhe Skov, VP – Head of Media Relations | +45 3054 1227 | ORSK@cip.com

Legal disclaimer

This release does not constitute an offer to sell or the solicitation of an offer to purchase any security. Any investment involves substantial risks including complete loss of capital. There can be no assurance that CIP will be able to implement the strategy described herein or, if implemented, that it will lead to successful results. Similarly, there can be no assurance that CIP will be able to maintain the advantages discussed herein over time or outperform third parties or the financial markets generally.

Certain information contained herein constitutes “forward-looking statements,” which can be identified by the use of terms such as “may,” “will,” “expects,” “intends,” “plans,” “believes,” “estimates” or comparable terminology. Forward-looking statements are subject to a number of known and unknown risks and uncertainties, including without limitation changes in economic conditions, political changes, legal and regulatory requirements, interest rate fluctuations, as well as changes in markets, prospects and competition. There can be no assurance that historical trends will continue. Some of the views expressed herein are the opinions of CIP and should not be construed as absolute statements and are subject to change without notice.

GlobeNewswire Distribution ID 1000854241

Wuhan, China – October 16, 2023 – Atos has renewed its Value-Added Telecommunication Services licenses (VATS licenses) in China, enabling it to run world class digital services and data centers across the country. Atos Cloud Computing has retained the licenses since 2019, being the first authorized foreign-funded company to operate cloud computing VATS regulated activities in several Chinese cities including Beijing, Shanghai, and Wuhan.

The Ministry of Industry and Information Technology of the People’s Republic of China has renewed the Atos Cloud Computing Co. Ltd VATS licenses for a further 5 years to 2028. The VATS licenses stipulate that Atos Cloud Computing is qualified to provide Internet Data Center Services (covering multiple regions, referred to as “IDC”) and Online Data Processing and Transaction Processing Services for customers in China.

“This VATS licenses’ extension is a key milestone for Atos China, it means that we can continue to deliver world-class secure and compliant digital services supporting customers’ growth ambitions.” said Ruifeng Yun, Managing Director at Atos China Cloud Computing.

“The ability to serve our local and worldwide customers in China with regulated Data Center Services, Online Data Processing and Cloud Services is a distinctive capability that Atos is proud to bring to our partners in the region and globally. This five-year renewal underlines our strong working relationship with the Chinese Regulatory Authorities and our commitment to the Chinese market.” said Daniele Principato, CEO at Atos Asia Pacific.

In more detail, the Value-Added Telecommunication Services accreditation enables Atos in China to deliver:

Internet Data Center Services (covering multiple regions)

• IDC services, which include the placement, maintenance, system configuration and/or management services provided for users’ servers and other network equipment utilizing the corresponding data centers, as well as the rental of database systems, servers and other equipment, rental of the storage spaces of such equipment, proxy rental of communication lines and/or bandwidth, and/or other application services.
• Internet resource collaboration services, which include the data storage, internet application development environment, internet application deployment and operation management services provided for users through the internet by virtue of the equipment and resources established on the data centers in a manner of accessing and expanding on demand at any time and collaborative sharing.

Online Data Processing and Transaction Processing Services

• Online data processing and transaction/affair processing services through the internet by utilizing various kinds of online data and transaction/affair processing application platforms (including transaction processing services, electronic data exchange services and network/electronic equipment data processing services).

Read more about Atos cloud solutions here.

About Atos
Atos is a global leader in digital transformation with 107,000 employees and annual revenue of c. € 11 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea) and listed on Euronext Paris.

The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

About Tech Foundations
Tech Foundations is the Atos Group business line leading in managed services, focusing on hybrid cloud infrastructure, employee experience and technology services, through decarbonized, automated, and AI-enabled solutions. Its 52,000 employees advance what matters to the world’s businesses, institutions, and communities. It is present in 69 countries, with an annual revenue of € 6 billion.

Press contact
Olivia Yang | olivia.yang@atos.net | +86 10 6911 5481

Attachment

• PR – VATS – Atos CN – EN 20231016

GlobeNewswire Distribution ID 1000854003

BARCELONA, Spain, Oct. 15, 2023 (GLOBE NEWSWIRE) — Smart City Expo World Congress (SCEWC), the international summit on cities and smart urban solutions, organized by Fira De Barcelona, will hold its biggest edition to date in 2023. Taking place from November 7^th to 9^th, the event’s theme is “Welcome to the New Urban Era” and it is set to break records with a 55% increase in exhibition floorspace and 20% more attendees compared to previous years. Over 1,000 exhibitors, 25,000 delegates, and representatives from more than 800 cities and 140 countries are expected to travel to Barcelona.

SCEWC is a global showcase for innovative urban solutions and projects that focus on transforming cities into more sustainable, efficient, and livable spaces. To achieve this goal, the congress will structure its program into eight main tracks: Enabling Technologies, Energy & Environment, Mobility, Governance, Living & Inclusion, Economy, Infrastructure & Buildings, Safety & Security, and Blue Economy.

The event will feature a lineup of 600 speakers, including notable figures such as computer scientist and expert in Algorithmic bias Margaret Mitchell, AI-specialized lawyer Micaela Mantegna, and sustainable development expert Claire O’Neill, the former UK Minister for Energy & Clean Growth.

Airbnb and FC Barcelona, keynotes

Amongst the highlights of SCEWC are the keynotes from Airbnb and FC Barcelona. The co-founder and Chief Strategy Officer of Airbnb, Nathan Blecharczyk, who will discuss how the company faces the future and wants to help tackle overtourism through new features to help disperse guests and benefits across Europe.

The representatives of FC Barcelona will explain how the club is leading the transformation of the surroundings of its stadium to redefine the urban fabric through enhanced infrastructure and sustainability aiming to build a new city landmark and improve the quality of life for its residents.

In addition, SCEWC has fully booked its exhibition floorspace, with companies such as AWS, Aramco, Axis, Cisco, Dassault Systemes, Dell, Deloitte, FCC, Honeywell, Microsoft, Nvidia, PWC, Roshn, Siemens, Smart Ports: Piers of the Future, and Veolia.

The event will also feature pavilions from cities and countries including Brazil, China, Estonia, France, Germany, India, Israel, Italy, Japan, Korea, Mexico, Nordics, Poland, Portugal, Saudi Arabia, and USA, among others.

SCEWC will feature three co-located events, Tomorrow.Building, Tomorrow.Mobility, and Tomorrow.BlueEconomy, that focus on specific topics such as construction, transportation, and the opportunities of the sea for coastal cities, further establishing Barcelona as a global hub for innovative urban solutions.

For media requests please contact:

Salvador Bilurbina
email: sbilurbina@firabarcelona.com
phone: +34628162674

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d0b5b3fa-5e84-4649-919e-accfcf53592e

GlobeNewswire Distribution ID 1000854243